Eagle Pharmaceuticals Inc. (EGRX)

59.16
0.40 0.68
NASDAQ : Health Technology
Prev Close 58.76
Open 58.93
Day Low/High 57.75 / 60.00
52 Wk Low/High 36.03 / 70.13
Volume 106.32K
Avg Volume 140.70K
Exchange NASDAQ
Shares Outstanding 14.86M
Market Cap 879.68M
EPS 2.20
P/E Ratio 19.77
Div & Yield N.A. (N.A)
Eagle Pharmaceuticals Founder, President & CEO Scott Tarriff Named EY Entrepreneur Of The Year® 2016 New Jersey Region

Eagle Pharmaceuticals Founder, President & CEO Scott Tarriff Named EY Entrepreneur Of The Year® 2016 New Jersey Region

Eagle Pharmaceuticals (NASDAQ:EGRX) is pleased to announce that Founder, President and CEO Scott Tarriff received the EY Entrepreneur Of The Year® 2016 Award in the Specialty Pharmaceutical category in New Jersey.

ALERT: Rosen Law Firm Reminds Eagle Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - EGRX

ALERT: Rosen Law Firm Reminds Eagle Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - EGRX

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals (EGRX) Weak On High Volume Today

Eagle Pharmaceuticals (EGRX) Weak On High Volume Today

Trade-Ideas LLC identified Eagle Pharmaceuticals (EGRX) as a weak on high relative volume candidate

Eagle Pharmaceuticals (EGRX) Showing Signs Of Perilous Reversal Today

Eagle Pharmaceuticals (EGRX) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Eagle Pharmaceuticals (EGRX) as a "perilous reversal" (up big yesterday but down big today) candidate

Eagle Pharmaceuticals (EGRX) Marked As A Barbarian At The Gate

Eagle Pharmaceuticals (EGRX) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Eagle Pharmaceuticals (EGRX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Eagle Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Eagle Pharmaceuticals, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Eagle Pharmaceuticals, Inc.

Noteworthy Friday Option Activity: EGRX, GOGO, GSAT

Noteworthy Friday Option Activity: EGRX, GOGO, GSAT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Eagle Pharmaceuticals, Inc. , where a total of 11,179 contracts have traded so far, representing approximately 1.1 million underlying shares.

Glancy Prongay & Murray Commences Investigation On Behalf Of Eagle Pharmaceuticals Inc. Investors

Glancy Prongay & Murray Commences Investigation On Behalf Of Eagle Pharmaceuticals Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc.

Kirby McInerney LLP Announces Class Action On Behalf Of Eagle Pharmaceuticals, Inc. Investors

Kirby McInerney LLP Announces Class Action On Behalf Of Eagle Pharmaceuticals, Inc. Investors

The law firm of Kirby McInerney LLP announced today that it has filed class action lawsuit in the United States District Court for the District of New Jersey against Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals To Present At Upcoming June Conferences

Eagle Pharmaceuticals To Present At Upcoming June Conferences

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) today announced that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at two upcoming...

Trade-Ideas: Eagle Pharmaceuticals (EGRX) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Eagle Pharmaceuticals (EGRX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Eagle Pharmaceuticals (EGRX) as a "perilous reversal" (up big yesterday but down big today) candidate

These 5 Stocks Are Ready to Break Out

These 5 Stocks Are Ready to Break Out

These stocks are within range of triggering breakout trades.

Eagle Pharmaceuticals (EGRX) Marked As A Dead Cat Bounce Stock

Eagle Pharmaceuticals (EGRX) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Eagle Pharmaceuticals (EGRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AHH, ARCC, ATU, BCRH, BFS, CFNB, FCE.A, FCE.B, FINL, HLF, LSCC, Q, RBC, SLRC, SNHY, WD Downgrades: BH, IVR, MTRN, PMC, TREE, TUP Initiations: EGRX, SEDG Read on to get TheStreet Quant Ratings' detailed report:

Biotech Gets a Lifeline

Biotech Gets a Lifeline

Solid earnings and the start of some M&A activity may be just what this sector needs to rise.

Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka Achieves 71% Total Market Share

Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka Achieves 71% Total Market Share

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced its financial results for the first quarter ended March 31, 2016.

2 Longs and 2 Shorts to Watch in the Stock Market

2 Longs and 2 Shorts to Watch in the Stock Market

Here are two longs and two shorts to watch as the stock market presents both technical breakout and breakdown opportunities.

2 Small-Cap Biotechs With Big Ambitions

2 Small-Cap Biotechs With Big Ambitions

Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.

Eagle Pharmaceuticals To Present At May Conferences

Eagle Pharmaceuticals To Present At May Conferences

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) announced today that management will present at two conferences in May as follows:     ...

Eagle Pharmaceuticals, Inc. To Discuss First Quarter 2016 Financial Results On May 9, 2016

Eagle Pharmaceuticals, Inc. To Discuss First Quarter 2016 Financial Results On May 9, 2016

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) announced today that the Company will release its 2016 first quarter financial results on Monday, May 9, 2016, before the market opens.

CMS Determines That Existing J-Code J9033 Adequately Describes BENDEKA (bendamustine Hydrochloride) Injection

CMS Determines That Existing J-Code J9033 Adequately Describes BENDEKA (bendamustine Hydrochloride) Injection

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company") announced today that the Centers for Medicare & Medicaid Services (CMS) indicated that the Level II HCPCS code J9033 adequately describes...

Commit To Buy Eagle Pharmaceuticals At $35, Earn 50.8% Annualized Using Options

Commit To Buy Eagle Pharmaceuticals At $35, Earn 50.8% Annualized Using Options

Investors considering a purchase of Eagle Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $37.09/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Eagle Pharmaceuticals And The National Institutes Of Health (NIH/NIDA) Enter Into Agreement To Explore Use Of Ryanodex In MDMA (Ecstasy) And Methamphetamine Intoxication

Eagle Pharmaceuticals And The National Institutes Of Health (NIH/NIDA) Enter Into Agreement To Explore Use Of Ryanodex In MDMA (Ecstasy) And Methamphetamine Intoxication

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it has entered into an agreement with the National Institutes of Health ("NIH")/National Institute on Drug Abuse ("NIDA") to explore...

FDA Does Not Grant Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine Hydrochloride Injection)

FDA Does Not Grant Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine Hydrochloride Injection)

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company") announced today that the U.

Here’s Why Eagle Pharmaceuticals (EGRX) Stock Plunged Today

Here’s Why Eagle Pharmaceuticals (EGRX) Stock Plunged Today

Eagle Pharmaceuticals (EGRX) stock closed down on heavy trading volume Friday after the FDA rejected its new drug application for its blood thinner drug Kangio.

Eagle Pharmaceuticals (EGRX) Stock Tumbles, FDA Rejects Blood Thinner Drug

Eagle Pharmaceuticals (EGRX) Stock Tumbles, FDA Rejects Blood Thinner Drug

Eagle Pharmaceuticals (EGRX) stock is sinking on Friday afternoon as the FDA rejected the company’s drug Kangio, which prevents blood clots in some patients undergoing heart surgery.

Oversold Conditions For Eagle Pharmaceuticals (EGRX)

Oversold Conditions For Eagle Pharmaceuticals (EGRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Eagle Pharmaceuticals Receives Complete Response Letter From FDA On KANGIO (RTU Bivalirudin) Application

Eagle Pharmaceuticals Receives Complete Response Letter From FDA On KANGIO (RTU Bivalirudin) Application

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) ("Eagle" or the "Company") today announced that it has received a Complete Response Letter from the U.

TheStreet Quant Rating: C+ (Hold)